Lilly's biggest clinical-stage opportunity, solanezumab, has already failed one expensive phase 3 trial. Success in a redesigned trial for the Alzheimer's hopeful could offset upcoming losses to patent expirations and give the company a chance to raise its dividend at an acceptable rate. Given the past failure, though, its chances are mighty slim.
Eli Lilly ($LLY) offered long-term evidence to show that its amyloid-busting drug solanezumab has a distinct impact on Alzheimer's disease among early-stage patients, pointing to a delayed-start 3.5-year extension study, with a group of patients from the original placebo arm continuing to lag right behind patients who started on the drug at the beginning. there may not be meaningful new news on solanezumab until late 2016 or early 2017 when EXP 3 reports out."